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forms of hepatitis, with a concordance between the evaluations
performed through the two scoring systems.
2. The severity of the necroinﬂamatory lesions progressed paral-
lel to the patients’ age.
3. Irrespective of the scoring system used, the necroinﬂamatory
activity – evaluated at different levels – correlated with the
stages of ﬁbrosis.
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Objective: To analyze the neutralization activity against HCV of
sera from hepatitis C patients.
Methods: A eukaryotic expression plasmid encoding carboxyl
terminal-truncated HCV envelope protein 2 (E2) was transfected
into human 293T cells. Both intracellular E2 and secreted E2
protein could be detected by western blot analysis. The intracel-
lular E2 was used to assay anti-E2 antibodies in sera of hepatitis
C patients by ELISA. The full-length envelope protein expression
plasmid was transfected into 293 T cells and the reactivity of
transfectant with anti-E2 IgG positive sera were analyzed by
immunoﬂuorescence. Five strains of HCV pseudotype particle
(HCVpp) and two strains of cell cultured HCV (HCVcc) were used
to assay the neutralization activity of 12 anti-E2 positive sera
samples.
Results: ELISA showed 26 of 32 sera samples were anti-E2 IgG
positive. The intensity of intracellular green ﬂuorescence was
paralleled with anti-E2 antibodies level of the tested sera using
immunoﬂuorescence assay. For 12 sera samples with HCV RNA
positive, the virus load is negative correlated with anti-E2 an-
tibodies levels. The anti-E2 positive sera could neutralize ﬁve
strains of HCVpp and two strains of HCVcc at various degree,
and the neutralization activity was consistent with the anti-E2
antibodies levels.
Conclusion: The results suggested that cross-neutralization an-
tibodies against HCV are present in sera of hepatitis C pa-
tients, which indicated that development of vaccines that induce
broadly-reactive neutralization antibodies may be possible.
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Background: In humans, the type I interferon (IFN) family con-
sists of 13 IFN-α subtypes, IFN-β and IFN-ω; the type III IFN family
consists of IFN-λ1, -λ2 and -λ3. The biological signiﬁcance of the
existence of various IFN subtypes is not clear. Toll-like receptors
(TLR3, 7, 8, 9) can trigger interferon IFN-α, IFN-β and IFN-λ,
which are critical for antiviral immunity.
Methods: We investigated the 21 type I and III IFN subtypes in
chronic hepatitis C virus (HCV) infection after completed IFN
treatment for more than 3 months.
Result: Following different stimulations (Poly I:C for TLR3, Cl097
for TLR7/8, CpG-A for TLR9, HSV-1, VSV), constitutive expression
of IFN subtypes is different for different therapeutic outcome.
IFN-β is the most speciﬁc subtype induced in PBMC from HCV
patients for different therapeutic outcome. IFN-α2, α5, α7, α14,
α17, λ1 and ω are also speciﬁc for different outcome.
Conclusion: Some IFN subtype expressions correlate with anti-
HCV treatment result.
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Aims: Our aim was to evaluate the relationship between chronic
hepatitis C (CHC) and development of diabetes mellitus (DM) or
steatosis in comparison with chronic hepatitis B (CHB).
Methods: This study consisted of 192 patients, including 82 CHC
and 110 CHB. The histological activity and ﬁbrosis and steato-
sis in liver biopsy specimens were assessed in every patients.
The serum parameters including alanine aminotransferase (ALT),
total cholesterol (CHO), triglyceride (TG) levels and fasting
plasmatic glucose were tested.
Results: The prevalence of DM in the CHC and CHB groups was
14.3%, 6.6%, respectively (CHC vs CHB, P<0.005), Steatosis was
detected in 39 out of 82 specimens (47.6%) and in 33 out of 110
CHB (28.2%) (CHC vs CHB, P<0.005), The ALT levels and the HCV
RNA load is higher in CHC with steatosis than that in in CHC
without steatosis, The triglyceride and cholesterol levels were
signiﬁcantly lower in CHC (with and without steatosis)than that
in CHB.
Conclusions: CHC patients showed a higher prevalence of DM
and steatosis than CHB patients. Lipid metabolism inﬂuences the
replication of HCV and liver injury.
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Objective: To investigate the modes of transmission and treat-
ment outcome in chronic hepatitis C patients.
Methods: we analyzed the clinical data of 110 patients diagnosed
as chronic hepatitis C, and recorded the modes of transmission,
clinical manifestation and the feature of laboratory examination.
We long-term followed up the patients during therapy.
Result: 35.5% of the patients was found on blood or blood prod-
ucts transfusion, 44 patients on surgery and trauma operation
(40%). The rate of HCV genotype 1b and 2a is 50.9% and 16.4%
respectively. The rate of viral load at 10c and 106 IU/ml is 27.3%
and 38.2% respectively. Obvious clinic presentation is observed
in 20.9% of patients, and 79.1% does not have obvious hepatitis
symptom and physical sign. Total SVR rate is 64.9%, genotype 1
is 54.3%, non-1 is up to 83.3%. Fever, fatigue and the decreasing
of WBC and neutrophilic granulocyte are the predominate side
effects during therapy. SVR rate is correlated with HCV genotype,
age and viral load, whereas there is no relation to ALT level.
Conclusion: The predominant modes of transmission is blood
transfusion or the using of blood products. However, surgery
and trauma operation should be paid more attention, especially
traditional Chinese medicine acupuncture. Coinfection with HBV
accounts for a certain proportion. The most common genotypes
are 1b and 2a. There is no obvious hepatitis symptom and phys-
ical sign. The impact factors on SVR are predominately HCV
genotype, RNA level and age, whereas the serum ALT level is not
signiﬁcant impact factor.
